Immunohistochemical staining of Cyclin D1 of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Cyclin D1 [DCS-6] Antibody (cGMP).

Name: Cyclin D1 [DCS-6] Antibody (cGMP).
Brand: enQuire Bio
Price: 135 USD
Availability: InStock

$ 135.00 – $ 725.00

Please Select Product Options Below To View The Catalog Number.

SKU: QIVD101
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG2a

Product Number	Description	Price
QIVD101-0.1ml	Size: 0.1 ml, Format: Concentrate	$ 135.00
QIVD101-0.5ml	Size: 0.5 ml, Format: Concentrate	$ 445.00
QIVD101-1ml	Size: 1 ml, Format: Concentrate	$ 725.00
QIVD101-6ml	Size: 6 ml, Format: Predilute	$ 245.00

Shipping Information

In Stock

Flat Rate Shipping Anywhere in the US: $45

Datasheets and Documentation

Product Datasheet

Certificate of Analysis and Tags (Coming Soon)

SKU: QIVD101-0.1ml

Cyclin D1 General Information
Alternate Names

Molecular Weight
33.7 kDa
Chromosomal Location
q13.3 [chr: 11] [chr_start: 69641087] [chr_end: 69654474] [strand: 1]
Curated Database and Bioinformatic Data
Gene Symbol	CCND1
Entrez Gene ID	595
RefSeq Protein Accession(s)	NP_444284
RefSeq mRNA Accession(s)	NM_053056;
RefSeq Genomic Accession(s)	NC_000011; NG_007375
UniProt ID(s)	P24385
PharmGKB ID(s)	PA75
KEGG Gene ID(s)	hsa:595
Associated Diseases (KEGG IDs)	A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.; A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.; Multiple myeloma (MM) [MIM:254500]: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. {ECO:0000269\|PubMed:8695815}. The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
General Description of Cyclin D1 .
This antibody is specific to human cyclin D1. The cyclin D1 gene is located on 11q13 and has been shown to be amplified in a variety of tumors. Maximum expression of cyclin D1 occurs at a critical point in mid to late G1 phase of the cell cycle.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.

Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.

Application Notes

Specification	Recommendation
Recommended Dilution (Conc)	1:25-1:50
Pretreatment	EDTA Buffer pH 8.0
Incubation Parameters	30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal

Anti-Cyclin D1 Antibody Clone: DCS-6

Host and Isotype: Mouse IgG2a

Recommended Positive Control Sample: Breast carcinoma

Cellular Localization of Antibody DCS-6 Staining: Nuclear

Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN₃

Antibody Concentration: Lot specific. Plese contact tech support for data.

Immunogen: Prokaryotic recombinant fusion protein corresponding to human cyclin D1.

Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Cyclin D1 Information for Pathologists

Summary:

Cyclin D1 is also known as BCL1, B Cell Lymphoma #1, CCND1. Coded by BCL1 / PRAD1 (parathyroid adenoma 1) gene on #11q13. Responsible for transition to S phase by phosphorylating the retinoblastoma gene product, which releases transcription factors to initiate DNA replication. Overexpression promotes transformation to a malignant phenotype; overexpressed in many tumors. Cyclin D1 genotypes may be associated with nasopharyngeal carcinoma risk (Anticancer Res 2012;32:1093).

Common Uses By Pathologists:

Interpretation: nuclear stain. Mantle cell lymphoma: characterized by t(11;14) translocation, which places the cyclin D1 gene next to an immunoglobulin heavy chain enhancer gene; among lymphomas, cyclin D1 expression is very specific for mantle cell lymphoma; however, blastoid cases may be negative (Am J Surg Pathol 2012;36:214). Parathyroid: overexpressed in 40% of parathyroid adenomas, strong staining in carcinomas. Microscopic (histologic) images Images hosted on Pathout server:.

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.